Get the up-to-date Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use Form FDA 356h 2024 now

Get Form
Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use Form FDA 356h Preview on Page 1

Here's how it works

01. Edit your form online
01. Edit your form online
Type text, add images, blackout confidential details, add comments, highlights and more.
02. Sign it in a few clicks
02. Sign it in a few clicks
Draw your signature, type it, upload its image, or use your mobile device as a signature pad.
03. Share your form with others
03. Share your form with others
Send it via email, link, or fax. You can also download it, export it or print it out.

How to quickly redact Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use Form FDA 356h online

Form edit decoration
9.5
Ease of Setup
DocHub User Ratings on G2
9.0
Ease of Use
DocHub User Ratings on G2

Dochub is a perfect editor for modifying your forms online. Adhere to this simple guide to edit Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use Form FDA 356h in PDF format online free of charge:

  1. Register and log in. Register for a free account, set a secure password, and go through email verification to start managing your templates.
  2. Upload a document. Click on New Document and choose the file importing option: add Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use Form FDA 356h from your device, the cloud, or a protected URL.
  3. Make adjustments to the sample. Take advantage of the top and left panel tools to redact Application to Market a New Drug, Biologic, or an Antibiotic Drug for Human Use Form FDA 356h. Insert and customize text, images, and fillable fields, whiteout unneeded details, highlight the significant ones, and provide comments on your updates.
  4. Get your paperwork accomplished. Send the form to other people via email, create a link for faster file sharing, export the sample to the cloud, or save it on your device in the current version or with Audit Trail added.

Discover all the advantages of our editor today!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.
Contact us
(i) A Type 3 NDA is for a new dosage form of an active ingredient that has been approved or marketed in the United States (U.S.) by the same or another applicant but in a different dosage form. The indication for the drug product does not need to be the same as that of the already marketed drug product. 42 CFR 413.234 -- Drug designation process. - eCFR ecfr.gov part-413 subpart-H section-413 ecfr.gov part-413 subpart-H section-413
Application Types Investigational New Drug (IND) Application. IND Forms and Instructions. New Drug Applications (NDAs) NDA Forms and Electronic Submissions. Abbreviated New Drug Application (ANDA) ANDA Forms and Submission Requirements. Drug Master Files (DMFs) DMF Submission Resources. Forms Submission Requirements - FDA Food and Drug Administration (.gov) drugs forms-submission-require Food and Drug Administration (.gov) drugs forms-submission-require
Form FDA 1571: Coversheet for all IND submissions. The 1571 must be signed by the Sponsor of the IND. Form FDA 1572: Statement of Investigator. The 1572 must be signed by the Principal Investigator of the clinical trial.
Electronic Submissions All ANDA submissions MUST be in eCTD format. eCTD submission sizes 10 GB or less must use the FDA Electronic Submission Gateway (ESG). If an eCTD submission is greater than 10 GB, it may be submitted via physical media (DVD/USB Drive) to the CDER Document Room or via ESG.
NDA Forms and Electronic Submissions Form FDA-356h. Application to Market a New Drug, Biologic, or An Antibiotic Drug For Human Use. Form FDA-3397. Form FDA-3331. Guidance Documents for Electronic Submissions. For more information on electronic submissions, see Electronic Regulatory Submissions and Review Helpful Links.
be ready to get more

Complete this form in 5 minutes or less

Get form

People also ask

To align with PDUFA VII , BsUFA III, and GDUFA III requirements as well as make other improvements to data quality and ease of use, FDA has revised form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and form 1571: Investigational New Drug Application (IND).
Difference Between NDA and ANDA If the NDA is approved, then the product may be marketed in the United States. ANDA means Abbreviated New Drug Application. An abbreviated new drug application (ANDA) contains data that, when submitted to the FDA, provides for the review and ultimate approval of a generic drug product.
This form is officially known as the Application to Market a New or Abbreviated New Drug or Biologic for Human Use, and it is submitted to the U.S. Food and Drug Administration (FDA) as part of the regulatory process for gaining approval to market a new drug or biologic product.
The FDA Form 1571 or 1571 is the IND application cover page and it must accompany the initial IND submission and any amendments, IND safety reports, annual reports or general correspondence the sponsor submits to the FDA about the IND. The 1571 is a contractual agreement between the sponsor and the FDA.
Foreign Drug Establishment. Collection of GDUFA fees is initiated by industry by filling out a GDUFA cover sheet, (FDA Form 3794), for each of the following human generic drug user fees: ANDA and PAS (Note that a cover sheet is not required for all ANDA and PAS amendments)

Related links